Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis

被引：0
|
作者：
Michael Pfeifer
Raymond R. Townsend
Michael J. Davies
Ujjwala Vijapurkar
Jimmy Ren
机构：
[1] Janssen Scientific Affairs,Perelman School of Medicine
[2] LLC,undefined
[3] University of Pennsylvania,undefined
[4] Janssen Research & Development,undefined
[5] LLC,undefined
来源：
Cardiovascular Diabetology | / 16卷
关键词：
Canagliflozin; Sodium glucose co-transporter 2 (SGLT2) inhibitor; Type 2 diabetes; Blood pressure; Ambulatory blood pressure monitoring; Pulse pressure; Mean arterial pressure; Double product;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Effect of Food on the Pharmacokinetics of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, and Assessment of Dose Proportionality in Healthy Participants
    Devineni, Damayanthi
    Manitpisitkul, Prasarn
    Murphy, Joseph
    Stieltjes, Hans
    Ariyawansa, Jay
    Di Prospero, Nicholas A.
    Rothenberg, Paul
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2015, 4 (04): : 279 - 286
  • [42] Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on the pharmacokinetics of oral contraceptives, warfarin, and digoxin in healthy participants
    Devineni, Damayanthi
    Manitpisitkul, Prasarn
    Vaccaro, Nicole
    Bernard, Apexa
    Skee, Donna
    Mamidi, Rao N. V. S.
    Tian, Hong
    Weiner, Sveta
    Stieltjes, Hans
    Sha, Sue
    Rothenberg, Paul
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2015, 53 (01) : 41 - 53
  • [43] Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease A protocol for systematic review and meta-analysis
    Yu, Baisong
    Dong, ChunXia
    Hu, ZhiJuan
    Liu, Bing
    MEDICINE, 2021, 100 (08) : E24655
  • [44] Early effects of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes: study based on continuous glucose monitoring
    Torimoto, Keiichi
    Okada, Yosuke
    Koikawa, Kenji
    Tanaka, Yoshiya
    DIABETOLOGY & METABOLIC SYNDROME, 2017, 9
  • [45] Sotagliflozin: a dual sodium-glucose co-transporter-1 and-2 inhibitor for the management of Type 1 and Type 2 diabetes mellitus
    Sims, H.
    Smith, K. H.
    Bramlage, P.
    Minguet, J.
    DIABETIC MEDICINE, 2018, 35 (08) : 1037 - 1048
  • [46] Efficacy and safety of sodium-glucose co-transporter 2 inhibitors in the elderly versus non-elderly patients with type 2 diabetes mellitus: a meta-analysis
    Wang, Yao
    Shao, Xian
    Liu, Zewen
    ENDOCRINE JOURNAL, 2022, 69 (06) : 669 - 679
  • [47] Pharmacokinetic and Pharmacodynamic Profile of Empagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor
    Scheen, Andre J.
    CLINICAL PHARMACOKINETICS, 2014, 53 (03) : 213 - 225
  • [48] Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors
    Rahelic, Dario
    Javor, Eugen
    Lucijanic, Tomo
    Skelin, Marko
    ANNALS OF MEDICINE, 2017, 49 (01) : 51 - 62
  • [49] Preclinical Studies of Canagliflozin, a Sodium-Glucose Co-Transporter 2 Inhibitor, and Donepezil Combined Therapy in Alzheimer's Disease
    Stanciu, Gabriela Dumitrita
    Ababei, Daniela Carmen
    Solcan, Carmen
    Bild, Veronica
    Ciobica, Andrei
    Beschea Chiriac, Sorin-Ioan
    Ciobanu, Loredana Maria
    Tamba, Bogdan-Ionel
    PHARMACEUTICALS, 2023, 16 (11)
  • [50] Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study
    Nicolle, L. E.
    Capuano, G.
    Ways, K.
    Usiskin, K.
    CURRENT MEDICAL RESEARCH AND OPINION, 2012, 28 (07) : 1167 - 1171
12345